Last updated on February 2019

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+ HER2- Advanced Breast Cancer


Brief description of study

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.

Detailed Study Description

To provide access to palbociclib to post-menopausal patients with hormone receptor-positive [HR(+)], HER2-negative [HER2(-)] ABC who are deemed appropriate for letrozole therapy.

Clinical Study Identifier: NCT02679755

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Icon Cancer Care Chermside
Chermside, Australia

Pfizer CT.gov Call Center

Haematology & Oncology Clinics of Australia Pty Ltd trading as Icon Cancer Care Corporate Office
South Brisbane, Australia
6.32miles

Pfizer CT.gov Call Center

Icon Cancer Care South Brisbane
South Brisbane, Australia
6.32miles

Pfizer CT.gov Call Center

Icon Cancer Foundation
South Brisbane, Australia
6.32miles

Pfizer CT.gov Call Center

Icon Cancer Care Wesley
Auchenflower, Australia
6.61miles

Pfizer CT.gov Call Center

River City Pharmacy
Auchenflower, Australia
6.61miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.